Research square · 2025
Comparing the predictive value of plasma p-tau217 and CSF biomarkers (p-tau181, Aβ42) using amyloid positron emission tomography in Alzheimer's continuum.
СтатьяПрепринтНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Azaraein Mohammad Hossein, Zarrazvand Elham, Heydari Fatemeh, Asimi Nasim, Ramezannezhad Elham, Rahimipour Deniz, Janeshin Kimia, Mahdian Aida, Sichani Maryam Fallahpour, Farhadi Shaghayegh, Zamiri Razieh, Amirian Mohammad Amir, Bemanalizadeh Maryam
Аннотация
INTRODUCTION: This study explores the diagnostic accuracy of different biomarkers for Alzheimer's disease (AD) using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI).
METHODS: A cross-sectional analysis was performed on individuals with mild cognitive impairment. Key biomarkers assessed included plasma p-tau217, CSF p-tau181, CSF Aβ42, and amyloid PET imaging, alongside clinical assessments using the Clinical Dementia Rating (CDR) and the Alzheimer's Disease Assessment Scale (ADAS).
RESULTS: Plasma p-tau217 showed the strongest correlation with amyloid-β deposition and clinical scores (Adjusted R2 = 0.53 for ADAS, 0.51 for CDR), outperforming CSF Aβ42 and CSF p-tau181.
DISCUSSION: These results suggest that plasma p-tau217 may serve as a more accurate, cost-effective, and non-invasive alternative to CSF biomarkers and PET imaging. Its superior predictive power highlights its potential in routine clinical settings for early diagnosis and monitoring of AD progression, addressing key challenges in accessibility and patient compliance associated with current diagnostic methods.
METHODS: A cross-sectional analysis was performed on individuals with mild cognitive impairment. Key biomarkers assessed included plasma p-tau217, CSF p-tau181, CSF Aβ42, and amyloid PET imaging, alongside clinical assessments using the Clinical Dementia Rating (CDR) and the Alzheimer's Disease Assessment Scale (ADAS).
RESULTS: Plasma p-tau217 showed the strongest correlation with amyloid-β deposition and clinical scores (Adjusted R2 = 0.53 for ADAS, 0.51 for CDR), outperforming CSF Aβ42 and CSF p-tau181.
DISCUSSION: These results suggest that plasma p-tau217 may serve as a more accurate, cost-effective, and non-invasive alternative to CSF biomarkers and PET imaging. Its superior predictive power highlights its potential in routine clinical settings for early diagnosis and monitoring of AD progression, addressing key challenges in accessibility and patient compliance associated with current diagnostic methods.